Skip To Main Content
Coburn Hobar on Muck Rack

Coburn Hobar

As seen in: Wiley Online Library, The BMJ
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Coburn

Contact Coburn, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Deucravacitinib, an oral, selective, allosteric, tyrosine kinase 2 inhibitor, in patients with active SLE: efficacy on patient-reported outcomes in a phase II randomised trial

|
By Marta Mosca, Laurent Arnaud, Anca D. Askanase, Coburn Hobar
| The BMJ Verified
In a 48-week, double-blind, phase II trial that assessed deucravacitinib in patients with active SLE, deucravacitinib demonstrated efficacy across multiple endpoints compared with placebo, including the primary endpoint of Systemic Lupus Erythematosus Responder Index-4 at week 32 and key secondary endpoints at week 48.
Open in Who Shared Issue with article?
See all 1 articles